#USA #New York #Securities Class Action #Faruqi & Faruqi #Ultragenyx

Important Notice for Ultragenyx Pharmaceutical Investors

Ultragenyx Pharmaceutical Inc. is currently under scrutiny as a federal securities class action has been filed against it. Faruqi & Faruqi, LLP, a prominent national securities law firm, is reminding investors of the crucial deadline approaching on April 6, 2026. This date marks the end of the opportunity for investors who acquired securities in Ultragenyx between August 3, 2023, and December 26, 2025, to seek the role of lead plaintiff in this legal action.

Background of the Case

The securities litigation primarily arises from allegations that Ultragenyx and its executives misrepresented and failed to disclose critical information regarding their Phase III Orbit study. This study dealt with setrusumab, a drug intended to aid patients suffering from Osteogenesis Imperfecta (OI). Investors contend that the company created a deceptive impression that it had credible data on the drug's efficacy while underestimating the significant risks associated with the Phase III study outcomes.

As presented in the lawsuit, there were concerns that Ultragenyx did not adequately communicate the uncertainties tied to previous Phase II study results which lacked a placebo control group. These missteps allegedly induced investors to misjudge the potential effectiveness of the treatment, leading to significant financial losses once the results were publicly disclosed.

Significant Developments

On July 9, 2025, Ultragenyx reported troubling news as the Phase III Orbit study did not reach statistical significance during its second interim analysis. This revelation resulted in a more than 25% drop in the company’s stock price, starkly illustrating the breach of investor trust. Further compounding the situation, on December 29, 2025, it was disclosed that neither the Phase III Orbit nor Cosmic Studies achieved their primary endpoints compared to placebo or bisphosphonates. The aftermath saw the stock price plummet by more than 42%.

These events underscore the volatility and risks investors faced, and they raise essential questions about the accountability of Ultragenyx's management decisions and their adherence to federal securities laws.

The Role of Faruqi & Faruqi, LLP

The role of Faruqi & Faruqi, LLP extends beyond just filing the class action. They are encouraging any investor who has suffered losses relating to these developments to reach out directly to discuss legal options. Potential and interested plaintiffs can contact James (Josh) Wilson, a partner at the firm, either via phone or the firm’s dedicated website for more insights into participating in the case and ensuring their voices are heard.

For those wishing to act as lead plaintiffs, they must apply to the court; however, it is crucial to note that your ability to partake in any recoveries will remain intact regardless of your involvement in leading the case.

Furthermore, Faruqi & Faruqi also invites anyone with information regarding Ultragenyx’s practices—including whistleblowers or former employees—to come forward. The firm seeks to build a robust case that adequately represents the shareholders affected by these developments.

Conclusion

With the approaching deadline of April 6, 2026, it is crucial for investors affected by Ultragenyx's missteps to take action now to secure their rights. As this situation unfolds, continuous updates will be provided through various platforms, ensuring stakeholders remain informed. For any inquiries or to learn further about the steps ahead, all participants are encouraged to follow up with Faruqi & Faruqi, LLP. This could be a pivotal moment for shareholders to reclaim their stakes in a challenging market environment.

Stay informed, and don't miss your chance to be part of this significant legal opportunity. For more information, individuals can visit Faruqi Law or contact the firm's representatives directly.